FDA Greenlights Second Generic Mifepristone, Expanding Abortion Access Amid Political Scrutiny

The Food and Drug Administration (FDA) has approved a second generic version of the abortion medication mifepristone (200-mg oral tablets), a move that quietly, yet significantly, bolsters the supply chain for medication abortion in the United States. The approval, granted to Evita Solutions, LLC on a Tuesday (October 2, 2025), just before a potential midnight government shutdown, increases the total number of American manufacturers of the drug to three.

Key Details of the Approval

Manufacturer: Evita Solutions, LLC.
Product: Generic Mifepristone Tablets, 200 mg.
Indication: Medical termination of an intrauterine pregnancy through 70 days of gestation (10 weeks or less), in a regimen with misoprostol.
Launch Expectation: The manufacturer anticipates the new generic product will launch in January 2026.
Expanded Supply: This approval, following the first generic from GenBioPro (approved in 2019) and the original brand-name drug Mifeprex (Danco Laboratories), is expected to increase competition, potentially lower costs, and enhance access at a time when reproductive health services are under increasing state-level restrictions. Medication abortion accounts for approximately two-thirds of all pregnancy terminations in the U.S.

The Drug Regimen and Mechanism

The FDA-approved regimen for medical termination of pregnancy involves a two-drug process:

Mifepristone (200 mg oral tablet): Taken first, this drug is an antiprogestin that blocks the hormone progesterone, which is essential for sustaining the interior lining of the uterus and supporting the pregnancy. Its action stops the supply of necessary hormones.
Misoprostol (four 200 mcg oral doses): Administered 24 to 48 hours after mifepristone, this drug causes the uterus to contract and expel its contents, completing the abortion process.

Mifepristone is also indicated for an entirely separate condition: controlling high blood glucose in patients with Cushing syndrome who also have Type 2 diabetes and cannot undergo or have failed surgery.

Generic Review and Regulatory Compliance

Because Evita Solutions’ application was for a generic version, it was submitted as an Abbreviated New Drug Application (ANDA). This process requires the applicant to demonstrate that the generic is bioequivalent and therapeutically equivalent to the brand-name drug, rather than undergoing the full, rigorous safety and effectiveness trials required for a first-time drug approval.

Despite the typically quick 10-month turnaround for ANDA applications, filing documents show Evita Solutions submitted its application four years ago. A spokesperson for the Department of Health and Human Services (HHS), Andrew Nixon, affirmed the non-discretionary nature of the approval, stating, “By law, the Secretary of Health and Human Services (HHS) must approve an application if it demonstrates that the generic drug is identical to the brand-name drug.”

Crucially, the FDA emphasized that the new generic will be subject to the existing Mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program. This single, shared system includes strict safety protocols and Elements to Assure Safe Use (ETASU), which apply equally to all three manufacturers. Evita Solutions’ final proposed REMS was approved in April 2025, ensuring full compliance before the product enters interstate commerce.

Political Fallout and Safety Review

The quiet timing of the approval—issued via a letter rather than a public press release—came amid intense political pressure and a promised safety review of mifepristone by current administration health officials.

Conservative Backlash: Republican lawmakers and anti-abortion groups immediately criticized the decision, viewing it as contradictory to the administration’s pledge to conduct a “top-to-bottom safety review” of the drug. Critics like Senator Josh Hawley (R-Mo.) expressed a “loss of confidence” in the FDA’s leadership.
HHS Defense: The HHS spokesperson stressed that the generic approval was a legal requirement based on scientific parity, separate from the broader safety review the agency is now undertaking to ensure the existing REMS program is sufficient.
Reproductive Rights Support: Pro-choice organizations celebrated the approval as a victory for evidence-based medicine, reinforcing mifepristone’s decades-long record of safety and effectiveness. The approval is seen as a vital step in maintaining access as states continue to implement restrictions following the Supreme Court’s 2022 decision overturning Roe v. Wade.